| Summary: |
The most common neurodegenerative disease is Alzheimer's (AD), an irreversible, complex, and progressive neurological disease that cause memory decline and gradually leads to dementia and death. Current treatments
are only palliative and fail to modify the disease progression. Thus, there is a pressing need for disease-modifying drugs (DMDs). The AD neurodegenerative process relies on neuroinflammation, synaptic and cell loss, and
accumulation of aggregating pathological proteins (Amyloid-beta (Aβ) and Tau), among others. Massive oxidative tress sustains the neurodegenerative toxicity and accumulation of Aβ and Tau. Therefore, the use of effective
mitochondriotropic antioxidants can operate as a novel therapeutic strategy. This bilateral cooperation will allow to acquire pre-clinical data to validate novel mitochondria-targeted antioxidants (MTAs) as potential DMDs. The
project will combine the expertise of the Portuguese and French teams, both specialists in drug discovery and AD. |